[Multidrug-resistant tuberculosis management in three French hospitals]

Med Mal Infect. 2011 Jan;41(1):20-4. doi: 10.1016/j.medmal.2010.07.003.
[Article in French]

Abstract

Introduction: Multidrug-resistant tuberculosis (MDR-TB) management is based on specific WHO guidelines.

Objectives: The authors report MDR-TB management, in three French hospitals.

Method: The authors retrospectively included patients with positive sample for multidrug-resistant Mycobacterium tuberculosis (isoniazid+rifampicin) from January 1, 2000 to December 31, 2005. The management was compared to the French and international prevalent guidelines.

Results: Sixteen patients were initially managed for MDR-TB by eight different medical teams over 6 successive years: 12 (75%) presented with primary MDR-TB. Management advice from the national referee center (NRC) for tuberculosis was reported in seven out of 14 treated cases. The median length of the intensive treatment was 2 months (IQR: 1-3). Eight patients (58%) had an overall treatment length of 18 months. The median number of effective drugs prescribed was 4 (IQR: 4-5). Nine patients (64%) were also managed in a sanatorium. Only eight patients (57%) completed the prescribed treatment. Nine patients were clinically cured and still followed-up, six of whom were bacteriologically cured.

Conclusion: TB-MDR management was not conform to WHO guidelines in our study. Management in a sanatorium, NRC involvement, ambulatory DOT were highly beneficial.

Publication types

  • English Abstract
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Africa / ethnology
  • Antitubercular Agents / therapeutic use*
  • Asia / ethnology
  • Disease Management
  • Drug Therapy, Combination
  • Female
  • France / epidemiology
  • Hospitals, Chronic Disease / statistics & numerical data
  • Hospitals, Urban / statistics & numerical data
  • Humans
  • Male
  • Practice Guidelines as Topic
  • Retrospective Studies
  • Socioeconomic Factors
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Young Adult

Substances

  • Antitubercular Agents